ASH 2025 | Updated Data for Ascentage Pharma’s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
(HKSE:6855),(NasdaqGM:AAPG), 76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles Strong efficacy data support potential advancement to earlier treatment lines for a broader patient population ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 […]